Rocket Pharmaceuticals sells rare pediatric disease priority review voucher for $180 million
PUBT · 06/12 11:00
Share
Listen to the news
- Rocket Pharmaceuticals closed the sale of its Rare Pediatric Disease Priority Review Voucher for gross proceeds of USD 180 million.
- The voucher was awarded in March 2026 tied to the FDA approval of KRESLADI for severe leukocyte adhesion deficiency-I.
- Pro forma cash, cash equivalents, and investments rose to about USD 322.6 million from USD 144.4 million as of March 31, 2026.
- The company expects the added liquidity to fund operations into the second quarter of 2028.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rocket Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260612407717) on June 12, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved